Bank of America Corp DE Sells 1,098,430 Shares of Novo Nordisk A/S $NVO

Bank of America Corp DE lowered its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 9.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,769,699 shares of the company's stock after selling 1,098,430 shares during the quarter. Bank of America Corp DE owned about 0.24% of Novo Nordisk A/S worth $395,786,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Godfrey Financial Associates Inc. bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth approximately $25,000. WealthCollab LLC grew its position in Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company's stock valued at $27,000 after acquiring an additional 260 shares during the last quarter. American National Bank & Trust purchased a new stake in Novo Nordisk A/S in the fourth quarter worth $28,000. Jackson Grant Investment Advisers Inc. bought a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $29,000. Finally, Maseco LLP bought a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $29,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $47.20 on Monday. The company has a market capitalization of $210.74 billion, a PE ratio of 11.08, a P/E/G ratio of 4.30 and a beta of 0.76. The company has a 50-day simple moving average of $46.92 and a two-hundred day simple moving average of $45.40. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $64.16. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The business had revenue of $10.85 billion for the quarter. Research analysts expect that Novo Nordisk A/S will post 3.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NVO. Weiss Ratings restated a "sell (d+)" rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. HSBC reiterated a "hold" rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Citigroup restated a "neutral" rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Zacks Research lowered shares of Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a research report on Monday, July 13th. Finally, Nordea Equity Research raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Friday, June 19th. Five equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of "Hold" and an average price target of $65.56.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s existing obesity business remains a key support. The company recently received European approval for a once-daily Wegovy pill and partnered with Crux to expand access to Wegovy through U.S. employer health plans, potentially broadening distribution and affordability. Novo Nordisk Teams Up With Crux To Expand Wegovy Access
• Neutral Sentiment: Some investor commentary indicates that Novo Nordisk’s current revenue drivers, particularly its GLP-1 medicines, remain intact despite the pipeline setback. However, the failed trial increases reliance on those products for future growth. NVO Stock Slumps After Late-Stage Trial Fails Primary Goal
• Negative Sentiment: In the Phase 3 ZEUS trial, ziltivekimab failed to significantly reduce major adverse cardiovascular events versus placebo in patients with cardiovascular disease, chronic kidney disease and inflammation. The result eliminates or reduces the near-term commercial potential of a drug intended to expand Novo Nordisk’s cardiovascular portfolio. Novo Nordisk’s Inflammation Drug Fails to Reduce Cardiovascular Risk in Trial
• Negative Sentiment: The setback is weighing on investor confidence in Novo Nordisk’s pipeline and has pushed the stock lower as markets reassess future growth and valuation. Novo Nordisk Shares Dive After Heart Medicine Fails Trial
• Negative Sentiment: Erste Group Bank also trimmed its fiscal 2026 earnings estimate to $3.20 per share from $3.22, below the $3.39 consensus estimate, adding to the cautious outlook. Novo Nordisk Analyst Estimate Update

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.